MPL mutation analysis
MPL mutation analysis-13552
MPL W515 mutations are present in patients with primary myelofibrosis (PMF) and essential thrombocythemia (ET) at a frequency of approximately 5% and 1% respectively. The S505 mutation is detected in patients with hereditary thrombocythemia.
Immediately following collection, mix sample thoroughly by gently inverting 8 - 10, times to prevent clotting
Lavender (EDTA) tube
Bone marrow cell pellet
Dk green Sodium heparin (Na hep), no gel
Sterile vial/container
Molecular Medicare Billing Request
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.
Ambient
If specimen is to be stored prior to shipment, store at 2 - 8°C.
- Specimen does not meet collection criteria
- frozen whole blood, marrow, or cell pellet
- leaking tube
- clotted blood or marrow
- grossly hemolyzed specimen or otherwise visibly degraded
- contamination by another specimen
- specimens containing suspicious foreign material
Polymerase chain reaction (PCR) and DNA sequencing
An interpretive report will be provided
MPL (myeloproliferative leukemia virus oncogene homology) belongs to the hematopoietin superfamily and enables its ligand thrombopoietin to facilitate both global hematopoiesis and megakaryocyte growth and differentiation.
Hospital clients submitting a request for this assay on an outpatient with Medicare should complete and submit a Molecular Medicare billing request form to notify us of the need for Allina Health Laboratory to bill insurance.